Eisbach Bio is a clinical-stage biotechnology company developing next-generation cancer therapies with its proprietary ALLOS platform. By combining real biology, synthetic lethality, and AI-guided drug design, Eisbach creates targeted small-molecule treatments for genetically defined cancers with the goal of improving precision, reducing toxicity, and overcoming treatment resistance.